A recombinant rabies vaccine expressing the trimeric form of the glycoprotein confers enhanced immunogenicity and protection in outbred mice

Vaccine

Volumn 32, Issue 36, 2014, Pages 4644-4650

  Koraka, Penelope ^a   Bosch, Berend Jan ^b   Cox, Manon ^c   Chubet, Rick ^c   Amerongen, Geert van ^a,c   Lövgren Bengtsson, Karen ^d   Martina, Byron E E ^a   Roose, Jouke ^a   Rottier, Peter J M ^b   Osterhaus, Albert D M E ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c Protein Sciences Corp ^*  (Netherlands)

^d NOVAVAX INC   (United States)

Author keywords

Glycoprotein G; Matrix M ; Rabies; Vaccine

Indexed keywords

IMMUNOLOGICAL ADJUVANT; MATRIX M; MONOMER; NEUTRALIZING ANTIBODY; RABIES VACCINE; RECOMBINANT VACCINE; THROMBOSPONDIN; UNCLASSIFIED DRUG; GLYCOPROTEIN; GLYCOPROTEIN G, RABIES VIRUS; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; LOW DRUG DOSE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OUTBRED MOUSE STRAIN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABIES; SINGLE DRUG DOSE; ANIMAL; ANTIBODY PRODUCTION; BLOOD; IMMUNOLOGY; RABIES VIRUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY FORMATION; ANTIGENS, VIRAL; GLYCOPROTEINS; MICE; RABIES; RABIES VACCINES; RABIES VIRUS; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS;

EID: 84923073690     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.06.058     Document Type: Article

References (30)

1. WHO WHO expert consultation on rabies. World Health Organ Tech Rep Ser 2005, 931:1-88. (back cover).
2. WHO Rabies vaccines: WHO position paper-recommendations. Vaccine 2010, 28(44):7140-7142.
3. Hicks D.J., Fooks A.R., Johnson N. Developments in rabies vaccines. Clin Exp Immunol 2012, 169(3):199-204.
4. Gaudin Y., Ruigrok R.W., Tuffereau C., Knossow M., Flamand A. Rabies virus glycoprotein is a trimer. Virology 1992, 187(2):627-632.
5. Ashraf S., Singh P.K., Yadav D.K., Shahnawaz M., Mishra S., Sawant S.V., et al. High level expression of surface glycoprotein of rabies virus in tobacco leaves and its immunoprotective activity in mice. J Biotechnol 2005, 119(1):1-14.
6. Dietzschold B., Faber M., Schnell M.J. New approaches to the prevention and eradication of rabies. Expert Rev Vaccines 2003, 2(3):399-406.
7. Huang H., Xiao S., Qin J., Jiang Y., Yang S., Li T., et al. Construction and immunogenicity of a recombinant pseudotype baculovirus expressing the glycoprotein of rabies virus in mice. Arch Virol 2011, 156(5):753-758.
8. Kaur M., Saxena A., Rai A., Bhatnagar R. Rabies DNA vaccine encoding lysosome-targeted glycoprotein supplemented with Emulsigen-D confers complete protection in preexposure and postexposure studies in BALB/c mice. FASEB J 2010, 24(1):173-183.
9. Li J., Faber M., Papaneri A., Faber M.L., McGettigan J.P., Schnell M.J., et al. A single immunization with a recombinant canine adenovirus expressing the rabies virus G protein confers protective immunity against rabies in mice. Virology 2006, 356(1-2):147-154. 5-20.
10. Bosch B.J., Bodewes R., de Vries R.P., Kreijtz J.H., Bartelink W., van Amerongen G., et al. Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets. J Virol 2010, 84(19):10366-10374.
11. Li W., Moore M.J., Vasilieva N., Sui J., Wong S.K., Berne M.A., et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003, 426(6965):450-454.
12. Bunschoten H., Gore M., Claassen I.J., Uytdehaag F.G., Dietzschold B., Wunner W.H., et al. Characterization of a new virus-neutralizing epitope that denotes a sequential determinant on the rabies virus glycoprotein. J Gen Virol 1989 Feb, 70(Pt 2):291-298.
13. Wilbur LAaA M.F.A. The NIH potency test. Laboratory techniques in rabies 1996, World Health Organization, Geneva. 4th ed. F.X. Meslin, M.M. Kalpan, H. Koprowski (Eds.).
14. Cliquet F., Aubert M., Sagne L. Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody. J Immunol Methods 1998, 212(1):79-87.
15. Wakeley P.R., Johnson N., McElhinney L.M., Marston D., Sawyer J., Fooks A.R. Development of a real-time, TaqMan reverse transcription-PCR assay for detection and differentiation of lyssavirus genotypes 1, 5, and 6. J Clin Microbiol 2005, 43(6):2786-2792.
16. Koraka P., Martina B.E., Roose J.M., van Thiel P.P., van Amerongen G., Kuiken T., et al. In vitro and in vivo isolation and characterization of Duvenhage virus. PLoS Pathog 2012, 8(5):e1002682.
17. Kärber G. Beitrag zur behandlung kollektiver Reihenversuche. Arch Exp Pathol Pharmakol 1931, 162(4):480-483.
18. Lafon M., Wiktor T.J., Macfarlan R.I. Antigenic sites on the CVS rabies virus glycoprotein: analysis with monoclonal antibodies. J Gen Virol 1983, 64(4):843-851.
19. Blink E.J., Light A., Kallies A., Nutt S.L., Hodgkin P.D., Tarlinton D.M. Early appearance of germinal center-derived memory B cells and plasma cells in blood after primary immunization. J Exp Med 2005, 201(4):545-554.
20. Slifka M.K., Matloubian M., Ahmed R. Bone marrow is a major site of long-term antibody production after acute viral infection. J Virol 1995, 69(3):1895-1902.
21. Fu Z.F., Rupprecht C.E., Dietzschold B., Saikumar P., Niu H.S., Babka I., et al. Oral vaccination of racoons (Procyon lotor) with baculovirus-expressed rabies virus glycoprotein. Vaccine 1993, 11(9):925-928.
22. Prehaud C., Takehara K., Flamand A., Bishop D.H. Immunogenic and protective properties of rabies virus glycoprotein expressed by baculovirus vectors. Virology 1989, 173(2):390-399.
23. Li Y., Svehla K., Mathy N.L., Voss G., Mascola J.R., Wyatt R. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants. J Virol 2006, 80(3):1414-1426.
24. Sundling C., Forsell M.N., O'Dell S., Feng Y., Chakrabarti B., Rao S.S., et al. Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates. J Exp Med 2010, 207(9):2003-2017.
25. Yang X., Wyatt R., Sodroski J. Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers. J Virol 2001, 75(3):1165-1171.
26. Reimer J.M., Karlsson K.H., Lovgren-Bengtsson K., Magnusson S.E., Fuentes A., Stertman L. Matrix-M adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigen. PLoS One 2012, 7(7):e41451.
27. Cox R.J., Brokstad K.A., Haaheim L.R. Pandemic influenza vaccine development: time is of the essence. Expert Rev Vaccines 2006, 5(5):603-606.
28. Pedersen G.K., Madhun A.S., Breakwell L., Hoschler K., Sjursen H., Pathirana R.D., et al. T-helper 1 cells elicited by H5N1 vaccination predict seroprotection. J Infect Dis 2012, 206(2):158-166.
29. Gomme E.A., Wirblich C., Addya S., Rall G.F., Schnell M.J. Immune clearance of attenuated rabies virus results in neuronal survival with altered gene expression. PLoS Pathog 2012, 8(10):e1002971.
30. Simon I.D., van Rooijen N., Rose J.K. Vesicular stomatitis virus genomic RNA persists in vivo in the absence of viral replication. J Virol 2010, 84(7):3280-3286.